Akari Therapeutics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AKTX and other ETFs, options, and stocks.

About AKTX

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor.

CEO

Abizer Gaslightwala

CEOAbizer Gaslightwala

Employees

Employees9

Headquarters

Boston, Massachusetts

HeadquartersBoston, Massachusetts

Founded

2004

Founded2004

Employees

Employees9

AKTX Key Statistics

Market cap

26.09M

Market cap26.09M

Price-Earnings ratio

-0.11

Price-Earnings ratio-0.11

Dividend yield

—

Dividend yield—

Average volume

406.97K

Average volume406.97K

High today

$1.10

High today$1.10

Low today

$0.62

Low today$0.62

Open price

$0.7199

Open price$0.7199

Volume

3.43M

Volume3.43M

52 Week high

$3.85

52 Week high$3.85

52 Week low

$0.5714

52 Week low$0.5714

Akari Therapeutics

Why Robinhood?

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. Show more

AKTX Key Statistics

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor.